Benzinga.com17d
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...
Benzinga.com23d
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Also Read: Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood ...
BioSpace24d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
In March 2023, Sanofi and Novo came under fire from Sen. Bernie Sanders (I-Vt), who asked the companies to follow in the footsteps of fellow diabetes leader Eli Lilly and lower the price of their ...
Business Insider27d
FDA approves Sanofi biosimilar product for treatment of diabetes
The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...
Seeking Alpha27d
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The ...
FierceBiotech28d
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. A scheduled review by the study ...
Bloomberg L.P.28d
Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...
FierceBiotech29d
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators. Abcuro is targeting ...
Frontiers2y
Higher Consumption of Fruit and Vegetables Is Associated With Lower Worries, Tension and Lack of Joy Across the Lifespan
Sanofi Aventis and Sanofi-synthelabo, during the conduct of the study. RD received a Primary Growth Partnership grant via the Ministry of Primary Industries in New Zealand with Fonterra Co-operative ...
Business Standard10y
Sanofi invests Rs 90 cr in Apollo Sugar Clinics
Sanofi-Synthelabo India, a part of pharma major Sanofi group, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding. Through this investment, both Apollo and Sanofi ...